Cytokinetics (CYTK) Q1 2025 earnings summary

Executive summary

• FDA extended PDUFA date for aficamten to December 26, 2025, due to a REMS submission; no additional clinical data required.

• Strong commercial readiness and specialty cardiology pipeline progress, with advanced salesforce recruitment and launch planning in the US and Europe.

• Completed enrollment for ACACIA-HCM Phase 3 trial ahead of schedule; topline results expected in first half of 2026.

• Maintained ~$1.1 billion in cash, cash equivalents, and investments as of March 31, 2025.

• Collaboration and license agreements with Sanofi (China/Taiwan) and Bayer (Japan) for aficamten, with significant milestone and royalty potential.

Financial highlights

• Ended Q1 2025 with $1.1 billion in cash, cash equivalents, and investments, down from $1.2 billion at end of Q4 2024.

• R&D expenses rose to $99.8 million from $81.6 million year-over-year, including $11.7 million stock-based compensation.

• G&A expenses increased to $57.4 million from $45.5 million year-over-year, including $11.9 million stock-based compensation.

• Net loss for Q1 2025 was $161.4 million ($1.36/share) vs. $135.6 million ($1.33/share) in Q1 2024.

• Collaboration revenues were $1.6 million in Q1 2025, up from $0.8 million in Q1 2024.

Outlook and guidance

• Expect to launch aficamten in the US in the second half of 2025, pending FDA approval.

• EMA approval for aficamten anticipated in first half of 2026; Germany to be first European launch market.

• Top-line results from MAPLE-HCM expected in May 2025; ACACIA-HCM primary cohort results in first half of 2026.

• Full-year 2025 GAAP operating expense guidance maintained at $670–$710 million, including $110–$120 million in stock-based compensation.

• Existing cash and investments expected to fund operations for at least the next 12 months.